Thank you for attending.

Please proceed by clicking "Next Page" . To receive credit, you must complete the post-test, evaluation and proceed to the claim credit page.

Only attendees are eligible for credit.

Thank you for attending this course.

Please click "Next Page" to proceed to the posttest, evaluation, and claim your credit. You will have 2 weeks to claim your credit.

Scroll back to top

Details

Overview
Clinicians who evaluate patients for geographic atrophy (GA) face a daunting challenge. Although there are no approved therapies for the treatment of GA, there are numerous candidates at various stages of development. Keeping track of them all is a tall order. Join Drs. Sadda, Modi, and Baumal to learn about these potential therapies as well as risk factors that drive this disease, imaging modalities that are best suited for GA evaluation, and the type of lesions patterns that place patients at high risk for progression.

Note, you will be emailed a link to the posttest, evaluation, and credit, Saturday, October 1, 2022. You will have two weeks to claim your credit.
This activity is supported by an unrestricted medical educational grant from Apellis Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize the prevalence of AMD and GA and define the burden of illness linked specifically to GA
- Comprehend and explain the pathogenesis of GA
- Describe GA disease detection and factors influencing progression
- Appraise the therapies targeting GA that have been explored as well as those in the pipeline
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
SriniVas Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute
Professor of Ophthalmology
University of California – Los Angeles
Geffen School of Medicine
Los Angeles, CA

Yasha S. Modi, MD
Vitreoretinal Surgeon
NYU Langone Health
Tisch Hospital and
The Ambulatory Care Center
Associate Professor
Dept of Ophthalmology
Grossman School of Medicine
New York University
New York, NY

Caroline R. Baumal, MD
Professor of Ophthalmology
New England Eye Center
Tufts University School of Medicine
Boston, MA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
SriniVas Sadda, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Apellis Pharmaceuticals, Astellas, Bayer, CenterVue, 4DMT, Heidelerg, iveric Bio, Merck, NightStax. Novartis, Optos, Oxurion, Regeneron, and Roche/Genentech. Grant/Research Support: Carl Zeiss Meditec. Speakers Bureau: Carl Zeiss Meditec and Nidek. Research instruments: Carl Zeiss Meditec, CenterVue, Heidelberg, Nidek, Optos, and Topcon.
Yasha S. Modi, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan/AbbVie, Carl Zeiss Meditec, DORC, Genentech, Iveric Bio, and Théa Pharma.
Caroline R. Baumal, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Apellis, Genentech, Novartis, and Ora. Speaker's Bureau: Carl Zeiss Meditic and Regeneron Pharmaceuticals.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis Pharmaceuticals.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
This program is not affiliated with the official program of AAO 2022.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Why QoL Measures Change TED Management
Why QoL Measures Change TED Management
MinuteCE®
Why QoL Measures Change TED Management
Prem S. Subramanian, MD, PhD; Kimberly Cockerham, MD
1.00 program credit
- Prem S. Subramanian, MD, PhD
- Kimberly Cockerham, MD
1.00 program credit
Applying CAS, EUGOGO, VISA: A Micro Case
Applying CAS, EUGOGO, VISA: A Micro Case
MinuteCE®
Applying CAS, EUGOGO, VISA: A Micro Case
Prem S. Subramanian, MD, PhD; Andrea Lora Kossler, MD, FACS
1.00 program credit
- Prem S. Subramanian, MD, PhD
- Andrea Lora Kossler, MD, FACS
1.00 program credit
Understanding IGF-1R Inhibition: Mechanism & Clinical Implications
Understanding IGF-1R Inhibition: Mechanism & Clinical Implications
MinuteCE®
Understanding IGF-1R Inhibition: Mechanism & Clinical Implications
Prem S. Subramanian, MD, PhD; Andrea Lora Kossler, MD, FACS
1.00 program credit
- Prem S. Subramanian, MD, PhD
- Andrea Lora Kossler, MD, FACS
1.00 program credit